These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 15184207)

  • 1. Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate.
    Fardon TC; Lee DK; Haggart K; McFarlane LC; Lipworth BJ
    Am J Respir Crit Care Med; 2004 Nov; 170(9):960-6. PubMed ID: 15184207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate.
    Tayab ZR; Fardon TC; Lee DK; Haggart K; McFarlane LC; Lipworth BJ; Hochhaus G
    Br J Clin Pharmacol; 2007 Nov; 64(5):698-705. PubMed ID: 17509041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator.
    O'Connor B; Bonnaud G; Haahtela T; Luna JM; Querfurt H; Wegener T; Lutsky BN
    Ann Allergy Asthma Immunol; 2001 Apr; 86(4):397-404. PubMed ID: 11345282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-response effect for adrenal suppression with repeated twice daily inhaled fluticasone propionate and triamcinolone acetonide in adult asthmatics.
    Wilson AM; McFarlane LC; Lipworth BJ
    Am J Respir Crit Care Med; 1997 Oct; 156(4 Pt 1):1274-7. PubMed ID: 9351634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-response for adrenal suppression with hydrofluoroalkane formulations of fluticasone propionate and beclomethasone dipropionate.
    Fowler SJ; Orr LC; Wilson AM; Sims EJ; Lipworth BJ
    Br J Clin Pharmacol; 2001 Jul; 52(1):93-5. PubMed ID: 11453895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative clinical pharmacology of mometasone furoate, fluticasone propionate and fluticasone furoate.
    Daley-Yates PT; Deans A; Mehta R; Sousa AR
    Pulm Pharmacol Ther; 2022 Dec; 77():102171. PubMed ID: 36243386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses.
    Affrime MB; Kosoglou T; Thonoor CM; Flannery BE; Herron JM
    Chest; 2000 Dec; 118(6):1538-46. PubMed ID: 11115437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of inhaled mometasone furoate on growth velocity and adrenal function: a placebo-controlled trial in children 4-9 years old with mild persistent asthma.
    Skoner DP; Meltzer EO; Milgrom H; Stryszak P; Teper A; Staudinger H
    J Asthma; 2011 Oct; 48(8):848-59. PubMed ID: 21854342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays.
    Daley-Yates PT; Kunka RL; Yin Y; Andrews SM; Callejas S; Ng C
    Eur J Clin Pharmacol; 2004 Jun; 60(4):265-8. PubMed ID: 15114430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the effect of a large volume spacer on the systemic bioactivity of fluticasone propionate metered-dose inhaler.
    Dempsey OJ; Wilson AM; Coutie WJ; Lipworth BJ
    Chest; 1999 Oct; 116(4):935-40. PubMed ID: 10531156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of mometasone furoate dry powder inhaler and fluticasone propionate dry powder inhaler in patients with moderate to severe persistent asthma requiring high-dose inhaled corticosteroid therapy: findings from a noninferiority trial.
    Harnest U; Price D; Howes T; Sussman G
    J Asthma; 2008 Apr; 45(3):215-20. PubMed ID: 18415829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with inhaled mometasone furoate reduces short-acting β(2) agonist claims and increases adherence compared to fluticasone propionate in asthma patients.
    Navaratnam P; Friedman HS; Urdaneta E
    Value Health; 2011; 14(2):339-46. PubMed ID: 21402302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of mometasone furoate dry powder inhaler vs fluticasone propionate metered-dose inhaler in asthma subjects previously using fluticasone propionate.
    Wardlaw A; Larivee P; Eller J; Cockcroft DW; Ghaly L; Harris AG
    Ann Allergy Asthma Immunol; 2004 Jul; 93(1):49-55. PubMed ID: 15281471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparable morning versus evening administration of once-daily mometasone furoate dry powder inhaler.
    Zetterström O; Dahl R; Lindqvist A; Olsson P
    Respir Med; 2008 Oct; 102(10):1406-11. PubMed ID: 18640826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of mometasone furoate administered once-daily in the evening in patients with persistent asthma dependent on inhaled corticosteroids.
    D'Urzo A; Karpel JP; Busse WW; Boulet LP; Monahan ME; Lutsky B; Staudinger H
    Curr Med Res Opin; 2005 Aug; 21(8):1281-9. PubMed ID: 16083538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once-daily evening dosing of mometasone furoate administered via a dry powder inhaler does not adversely affect the hypothalamic-pituitary-adrenal axis.
    Kosoglou T; Cutler DL; Staudinger H; Herron JM
    Chest; 2010 Jan; 137(1):115-21. PubMed ID: 19749003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of intranasal triamcinolone acetonide and intranasal fluticasone propionate on short-term bone growth and HPA axis in children with allergic rhinitis.
    Skoner DP; Gentile D; Angelini B; Kane R; Birdsall D; Banerji D
    Ann Allergy Asthma Immunol; 2003 Jan; 90(1):56-62. PubMed ID: 12546339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhaler.
    Noonan M; Karpel JP; Bensch GW; Ramsdell JW; Webb DR; Nolop KB; Lutsky BN
    Ann Allergy Asthma Immunol; 2001 Jan; 86(1):36-43. PubMed ID: 11206236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of mometasone, fluticasone, and montelukast on bone mineral density in adults with asthma.
    Maspero J; Backer V; Yao R; Staudinger H; Teper A
    J Allergy Clin Immunol Pract; 2013; 1(6):649-55.e1. PubMed ID: 24565713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma.
    Nayak AS; Banov C; Corren J; Feinstein BK; Floreani A; Friedman BF; Goldsobel A; Gottschlich GM; Hannaway PJ; Lampl KL; Lapidus RJ; Lawrence M; Lumry W; Munk Z; Pearlman D; Scardella AT; Schenkel EJ; Segal AT; Segall N; Silverman B; Shneyer L; Nolop KB; Harrison JE
    Ann Allergy Asthma Immunol; 2000 Apr; 84(4):417-24. PubMed ID: 10795650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.